1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.
(
- Contribution to journal › Article
- 2022
-
Mark
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
(
- Contribution to journal › Article
- 2021
-
Mark
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
(
- Contribution to journal › Article
- 2007
-
Mark
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
(
- Contribution to journal › Article
- 2005
-
Mark
Estrogen receptor alpha and beta in breast cancer - gene expression profiles and clinical implications
2005)(
- Thesis › Doctoral thesis (compilation)